Adjunctive cannabidiol shows promise in trial for schizophrenia

A Phase 2 double‐blind, placebo‐controlled trial involving 88 patients with schizophrenia has found that cannabidiol used as adjunctive therapy with an antipsychotic resulted in significant improvement in positive symptoms over placebo. Treating clinicians also were more likely to report patient improvement for participants receiving adjunctive cannabidiol than for patients receiving adjunctive placebo.

Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Tags: What's New in Research Source Type: research